Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience

Rearrangement in the anaplastic lymphoma kinase (ALK) gene is one of the oncogenic drivers in non-small cell lung cancer (NSCLC) patients. Several ALK inhibitors (ALKis) have been developed and have demonstrated their efficacy, however the best treatment strategy for ALK positive NSCLC patients has...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: De Carlo, Elisa, Del Savio, Maria Chiara, Polesel, Jerry, Da Ros, Valentina, Berto, Eleonora, Santarossa, Sandra, Chimienti, Emanuela, Fratino, Lucia, Bearz, Alessandra
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2018
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5880608/
https://ncbi.nlm.nih.gov/pubmed/29632648
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24573
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados